Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at Arriaran Foundation

Renato Ocampo; Désirée Vera; Marcelo Wolff

Keywords: hiv, total cholesterol, triglycerides, dyslipidemia, VIH, dislipidemia, raltegravir, Triglicéridos, cambio de terapia anti-retroviral, colesterol total, antiretroviral therapy switching

Abstract

Background: The impact of switching antiretroviral therapy (ART) regimen for dyslipidemia management in HIV-infected (HIV+) patients has not been reported in Chile. Aim: To assess effectiveness and safety at 12 months after switching to raltegravir-based regimen for dyslipidemia management. Methods: Retrospective cohort of HIV+ patients receiving ART at Arriaran Foundation, with dyslipidemia switched to raltegravir-based regimen for lipid management. Results: 73 patients were included. receiving ART based in nonnucleoside reverse transcriptase inhibitor (NNRTI; 50,7%) or protease inhibitor (PI; 49,3%), with mixed dyslipidemia (42,5%) or isolated hypertriglyceridernia (57,5%). At baseline, median total cholesterol (TC) and triglycerides (TG) were 228 mg/dl and 420 mg/dl, respectively: undetectable viral load (VL) was present in 94,5% of patients. Backbone ART was switched in 58,4% and lipid-lowering therapy was used by 89,1% of them. At 12 months, there was a significant decrease in TG (-43,6%) and TC (-19,3%). No cases of virologic failure were observed, although 10,9% of patients had detectable VL at 12 months, mostly transient. Conclusions: Switching ART to raltegravir-based regimen in dyslipidemic patients receiving NNRTI or PI is associated with a significative decrease in TG and TC at 12 months. This strategy is safe, but VL can be increased temporarily.

Más información

Título según WOS: Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at Arriaran Foundation
Título según SCOPUS: Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at arriaran foundation [Efectividad y seguridad del cambio a esquema basado en raltegravir en pacientes con infección por VIH dislipidémicos bajo terapia anti-retroviral en fundación arriarán]
Título según SCIELO: Efectividad y seguridad del cambio a esquema basado en raltegravir en pacientes con infecci�n por VIH dislipid�micos bajo terapia anti-retroviral en Fundaci�n Arriar�n
Título de la Revista: REVISTA CHILENA DE INFECTOLOGIA
Volumen: 36
Número: 4
Editorial: SOC CHILENA INFECTOLOGIA
Fecha de publicación: 2019
Página de inicio: 490
Página final: 495
Idioma: Spanish
DOI:

10.4067/S0716-10182019000400490

Notas: ISI, SCIELO, SCOPUS